Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03593837
Other study ID # HQGZWWT
Secondary ID
Status Not yet recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date October 1, 2018
Est. completion date March 31, 2020

Study information

Verified date July 2018
Source Shanghai University of Traditional Chinese Medicine
Contact Qianqian Liang, researcher
Phone +8618917763347
Email liangqianqiantcm@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by swelling, pain, and synovial damage. Effective methods lack in the treatment of RA. A traditional prescription in use for thousands of years in China, Huang Qi Gui Zhi Wu Wu Tang(HQGZWWT)granule is still chosen to relive pain and prevent joint malformation in RA patients. However, no evidence-based medical research has been organized to assess the effectiveness and safety of HQGZWWT granules for RA.


Description:

Investigators will conduct a multicenter, randomized, double-blind, placebo-controlled clinical trial to determine whether HQGZWWT granules can relieve pain and protect joints. Investigators will randomly divide 120 patients with active arthritis for 3 months. Main measurements include ratio of 50 of ACR (American College of Rheumatology), change of DAS (28) from baseline to 3 months, and SHARP scores of van der Heijde from baseline to 12 months. SecondarymeasurementsincludeACR20, ACR70, Health Assessment Questionnaire-Disability Index (HAQ-DI), arthritis pain score, and Patient Global Assessment of Arthritis. The time points are set as baseline, 2 weeks, 1 month, 2 months, 3 months, 6 months and 12 months. In addition, the rate of change (score) in the ACR50 and DAS28 from the baseline to 2-week, 1-month, 2-month, 6-month, and 12-month follow-up are also the secondary outcome measures.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date March 31, 2020
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Adults with rheumatoid arthritis (score more then 5 of ACR (American College Of Rheumatology) /EULAR (European League Against Rheumatism), 2009 )

- moderate-to-severe disease activity (Disease Activity Score for 28-joint counts (DAS28) of more than 3.2

- an onset of symptoms within 12 months before enrollment, no prior exposure to more than 10mg oral glucocorticoids or biologic agents

- paid employment or unpaid but measurable work (e.g. caring for a family and home)

Exclusion Criteria:

- combined with other disease such as adjuvant arthritis, lupus arthritis, osteoarthritis and et al.

- abnormal liver and my kidney function

- pregnancy or have a plan of pregnancy,breast feeding women

- severe chronic or acute disease interfering with therapy attendance

- alcohol or substance abuse

Study Design


Intervention

Drug:
Huang qi gui zhi wu wu granule
Patients are given HQGZWWT granules (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg)
Huang qi gui zhi wu wu granule placebo
Patients are given HQGZWWT granules placebo (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Cui xuejun

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of ACR (American College of Rheumatology) 50 ACR (American College of Rheumatology) 50 is a standard to describe RA symptoms. ACR 50 is met when the number of tender joints reduces by =50%, the number of swollen joints by =50%, and at least 3 of the following 5 indexes improves by =50%:
Patient's assessment on arthritis pain using a visual analogue scale (VAS) of 0-100 mm, Patient global assessment on disease activity using VAS scale (0-10), Patient's assessment on physical function and disability (Health Assessment Questionnaire - Disability Index (HAQ-DI)), Acute phase reactant value, such as erythrocyte sedimentation rate (ESR) or C-reactive Protein (CRP) level
at 3 months
Primary changes of The Disease Activity Score (DAS) 28 The DAS28 is an index calculating the number of painful and swollen joints (28 joints, i.e. shoulders, elbows, wrists, metacarpophalangeal and proximal interphalangeal joints, and knees), erythrocyte sedimentation rate and the score of global assessment. The formula of DAS 28 is 0.56×v(28 painful joint count) + 0.28×v(28 swollen joint count) + 0.70× (ln ESR) + 0.014 ×GH. ESR refers to erythrocyte sedimentation rate. GH is the patient's general health visual analog scale (0-10 mm) from baseline to 3 months
Secondary changes of The Disease Activity Score (DAS) 28 The DAS28 is an index calculating the number of painful and swollen joints (28 joints, i.e. shoulders, elbows, wrists, metacarpophalangeal and proximal interphalangeal joints, and knees), erythrocyte sedimentation rate and the score of global assessment. The formula of DAS 28 is 0.56×v(28 painful joint count) + 0.28×v(28 swollen joint count) + 0.70× (ln ESR) + 0.014 ×GH. ESR refers to erythrocyte sedimentation rate. GH is the patient's general health visual analog scale (0-10 mm) from baseline to 2 weeks
Secondary changes of The Disease Activity Score (DAS) 28 The DAS28 is an index calculating the number of painful and swollen joints (28 joints, i.e. shoulders, elbows, wrists, metacarpophalangeal and proximal interphalangeal joints, and knees), erythrocyte sedimentation rate and the score of global assessment. The formula of DAS 28 is 0.56×v(28 painful joint count) + 0.28×v(28 swollen joint count) + 0.70× (ln ESR) + 0.014 ×GH. ESR refers to erythrocyte sedimentation rate. GH is the patient's general health visual analog scale (0-10 mm) from baseline to 1 month
Secondary changes of The Disease Activity Score (DAS) 28 The DAS28 is an index calculating the number of painful and swollen joints (28 joints, i.e. shoulders, elbows, wrists, metacarpophalangeal and proximal interphalangeal joints, and knees), erythrocyte sedimentation rate and the score of global assessment. The formula of DAS 28 is 0.56×v(28 painful joint count) + 0.28×v(28 swollen joint count) + 0.70× (ln ESR) + 0.014 ×GH. ESR refers to erythrocyte sedimentation rate. GH is the patient's general health visual analog scale (0-10 mm) from baseline to 6 months
Secondary changes of The Disease Activity Score (DAS) 28 The DAS28 is an index calculating the number of painful and swollen joints (28 joints, i.e. shoulders, elbows, wrists, metacarpophalangeal and proximal interphalangeal joints, and knees), erythrocyte sedimentation rate and the score of global assessment. The formula of DAS 28 is 0.56×v(28 painful joint count) + 0.28×v(28 swollen joint count) + 0.70× (ln ESR) + 0.014 ×GH. ESR refers to erythrocyte sedimentation rate. GH is the patient's general health visual analog scale (0-10 mm) from baseline to 12 months
Secondary Rate of ACR (American College of Rheumatology) 50 ACR (American College of Rheumatology) 50 is a standard to describe RA symptoms. ACR 50 is met when the number of tender joints reduces by =50%, the number of swollen joints by =50%, and at least 3 of the following 5 indexes improves by =50%:
Patient's assessment on arthritis pain using a visual analogue scale (VAS) of 0-100 mm, Patient global assessment on disease activity using VAS scale (0-10), Patient's assessment on physical function and disability (Health Assessment Questionnaire - Disability Index (HAQ-DI)), Acute phase reactant value, such as erythrocyte sedimentation rate (ESR) or C-reactive Protein (CRP) level
at 2 weeks
Secondary Rate of ACR (American College of Rheumatology) 50 ACR (American College of Rheumatology) 50 is a standard to describe RA symptoms. ACR 50 is met when the number of tender joints reduces by =50%, the number of swollen joints by =50%, and at least 3 of the following 5 indexes improves by =50%:
Patient's assessment on arthritis pain using a visual analogue scale (VAS) of 0-100 mm, Patient global assessment on disease activity using VAS scale (0-10), Patient's assessment on physical function and disability (Health Assessment Questionnaire - Disability Index (HAQ-DI)), Acute phase reactant value, such as erythrocyte sedimentation rate (ESR) or C-reactive Protein (CRP) level
at 1 month
Secondary Rate of ACR (American College of Rheumatology) 50 ACR (American College of Rheumatology) 50 is a standard to describe RA symptoms. ACR 50 is met when the number of tender joints reduces by =50%, the number of swollen joints by =50%, and at least 3 of the following 5 indexes improves by =50%:
Patient's assessment on arthritis pain using a visual analogue scale (VAS) of 0-100 mm, Patient global assessment on disease activity using VAS scale (0-10), Patient's assessment on physical function and disability (Health Assessment Questionnaire - Disability Index (HAQ-DI)), Acute phase reactant value, such as erythrocyte sedimentation rate (ESR) or C-reactive Protein (CRP) level
at 2 months
Secondary Rate of ACR (American College of Rheumatology) 50 ACR (American College of Rheumatology) 50 is a standard to describe RA symptoms. ACR 50 is met when the number of tender joints reduces by =50%, the number of swollen joints by =50%, and at least 3 of the following 5 indexes improves by =50%:
Patient's assessment on arthritis pain using a visual analogue scale (VAS) of 0-100 mm, Patient global assessment on disease activity using VAS scale (0-10), Patient's assessment on physical function and disability (Health Assessment Questionnaire - Disability Index (HAQ-DI)), Acute phase reactant value, such as erythrocyte sedimentation rate (ESR) or C-reactive Protein (CRP) level
at 6 months
Secondary Rate of ACR (American College of Rheumatology) 50 ACR (American College of Rheumatology) 50 is a standard to describe RA symptoms. ACR 50 is met when the number of tender joints reduces by =50%, the number of swollen joints by =50%, and at least 3 of the following 5 indexes improves by =50%:
Patient's assessment on arthritis pain using a visual analogue scale (VAS) of 0-100 mm, Patient global assessment on disease activity using VAS scale (0-10), Patient's assessment on physical function and disability (Health Assessment Questionnaire - Disability Index (HAQ-DI)), Acute phase reactant value, such as erythrocyte sedimentation rate (ESR) or C-reactive Protein (CRP) level
at 12 months
Secondary change score of Health Assessment Questionnaire - Disability Index The HAQ-DI measure shave eight dimensions of functional activity: pruning, dressing, rising, eating, walking, personal hygiene, reach, grip, and other routine activities. Each item has 4 degrees ranging from 0 to 3. "0" refers to "no functional difficulty", "1" to a bit of functional difficulty, "2" to very much functional difficulty, and "3" to no ability to work. HAQ-DI score 0-1 means mild to moderate functional difficulty; 1-2 means moderate to severe disability; and 2-3 means generally severe disability from baseline to 2 weeks
Secondary change score of Health Assessment Questionnaire - Disability Index The HAQ-DI measure shave eight dimensions of functional activity: pruning, dressing, rising, eating, walking, personal hygiene, reach, grip, and other routine activities. Each item has 4 degrees ranging from 0 to 3. "0" refers to "no functional difficulty", "1" to a bit of functional difficulty, "2" to very much functional difficulty, and "3" to no ability to work. HAQ-DI score 0-1 means mild to moderate functional difficulty; 1-2 means moderate to severe disability; and 2-3 means generally severe disability from baseline to 1 month
Secondary change score of Health Assessment Questionnaire - Disability Index The HAQ-DI measure shave eight dimensions of functional activity: pruning, dressing, rising, eating, walking, personal hygiene, reach, grip, and other routine activities. Each item has 4 degrees ranging from 0 to 3. "0" refers to "no functional difficulty", "1" to a bit of functional difficulty, "2" to very much functional difficulty, and "3" to no ability to work. HAQ-DI score 0-1 means mild to moderate functional difficulty; 1-2 means moderate to severe disability; and 2-3 means generally severe disability from baseline to 2 months
Secondary change score of Health Assessment Questionnaire - Disability Index The HAQ-DI measure shave eight dimensions of functional activity: pruning, dressing, rising, eating, walking, personal hygiene, reach, grip, and other routine activities. Each item has 4 degrees ranging from 0 to 3. "0" refers to "no functional difficulty", "1" to a bit of functional difficulty, "2" to very much functional difficulty, and "3" to no ability to work. HAQ-DI score 0-1 means mild to moderate functional difficulty; 1-2 means moderate to severe disability; and 2-3 means generally severe disability from baseline to 3 months
Secondary change score of Health Assessment Questionnaire - Disability Index The HAQ-DI measure shave eight dimensions of functional activity: pruning, dressing, rising, eating, walking, personal hygiene, reach, grip, and other routine activities. Each item has 4 degrees ranging from 0 to 3. "0" refers to "no functional difficulty", "1" to a bit of functional difficulty, "2" to very much functional difficulty, and "3" to no ability to work. HAQ-DI score 0-1 means mild to moderate functional difficulty; 1-2 means moderate to severe disability; and 2-3 means generally severe disability from baseline to 6 months
Secondary change score of Health Assessment Questionnaire - Disability Index The HAQ-DI measure shave eight dimensions of functional activity: pruning, dressing, rising, eating, walking, personal hygiene, reach, grip, and other routine activities. Each item has 4 degrees ranging from 0 to 3. "0" refers to "no functional difficulty", "1" to a bit of functional difficulty, "2" to very much functional difficulty, and "3" to no ability to work. HAQ-DI score 0-1 means mild to moderate functional difficulty; 1-2 means moderate to severe disability; and 2-3 means generally severe disability from baseline to 12 months
Secondary change score of Patient Assessment of Arthritis Pain from baseline to 2 weeks
Secondary change score of Patient Assessment of Arthritis Pain VAS score, the range is 0-10, more pain then bigger number from baseline to 1 month
Secondary change score of Patient Assessment of Arthritis Pain VAS score, the range is 0-10, more pain then bigger number from baseline to 2 months
Secondary change score of Patient Assessment of Arthritis Pain VAS score, the range is 0-10, more pain then bigger number from baseline to 3 months
Secondary change score of Patient Assessment of Arthritis Pain VAS score, the range is 0-10, more pain then bigger number from baseline to 6 months
Secondary change score of Patient Assessment of Arthritis Pain VAS score, the range is 0-10, more pain then bigger number from baseline to 12 months
Secondary change score of Patient Global Assessment of Arthritis the range is 0-10, more pain then bigger number from baseline to 2 weeks
Secondary change score of Patient Global Assessment of Arthritis the range is 0-10, more pain then bigger number from baseline to 1 month
Secondary change score of Patient Global Assessment of Arthritis the range is 0-10, more pain then bigger number from baseline to 2 months
Secondary change score of Patient Global Assessment of Arthritis the range is 0-10, more pain then bigger number from baseline to 3 months
Secondary change score of Patient Global Assessment of Arthritis the range is 0-10, more pain then bigger number from baseline to 6 months
Secondary change score of Patient Global Assessment of Arthritis the range is 0-10, more pain then bigger number from baseline to 12 months
Secondary change score of 36-item Short-Form Health Survey Questionnaire from baseline to 2 weeks
Secondary change score of 36-item Short-Form Health Survey Questionnaire The SF-36 measures eight dimensions, including vitality, body function, body aches, general health perceptions, body functions, emotional function, social function and mental health. SF-36 is widely used in the evaluation of quality of life in patients with rheumatoid arthritis from baseline to 1 month
Secondary change score of 36-item Short-Form Health Survey Questionnaire The SF-36 measures eight dimensions, including vitality, body function, body aches, general health perceptions, body functions, emotional function, social function and mental health. SF-36 is widely used in the evaluation of quality of life in patients with rheumatoid arthritis from baseline to 2 months
Secondary change score of 36-item Short-Form Health Survey Questionnaire The SF-36 measures eight dimensions, including vitality, body function, body aches, general health perceptions, body functions, emotional function, social function and mental health. SF-36 is widely used in the evaluation of quality of life in patients with rheumatoid arthritis from baseline to 3 months
Secondary change score of 36-item Short-Form Health Survey Questionnaire The SF-36 measures eight dimensions, including vitality, body function, body aches, general health perceptions, body functions, emotional function, social function and mental health. SF-36 is widely used in the evaluation of quality of life in patients with rheumatoid arthritis from baseline to 6 months
Secondary change score of 36-item Short-Form Health Survey Questionnaire The SF-36 measures eight dimensions, including vitality, body function, body aches, general health perceptions, body functions, emotional function, social function and mental health. SF-36 is widely used in the evaluation of quality of life in patients with rheumatoid arthritis from baseline to 12 months
Secondary change score of AIS Sleep Scale The Athens Insomnia Scale (AIS) can help patients quantitatively self-evaluate sleep disorders with a psychometric instrument that includes eight indicators for sleep induction, awakenings during the night, final awakening, total sleep duration, sleep quality during the night, wellbeing during the night, functioning capacity during the day time, and sleepiness during the day time. The score for each indicator ranges from 0 to 3, and the total score is 24 points. The higher the score, the worse the sleep quality, and vise versa from baseline to 2 weeks
Secondary change score of AIS Sleep Scale The Athens Insomnia Scale (AIS) can help patients quantitatively self-evaluate sleep disorders with a psychometric instrument that includes eight indicators for sleep induction, awakenings during the night, final awakening, total sleep duration, sleep quality during the night, wellbeing during the night, functioning capacity during the day time, and sleepiness during the day time. The score for each indicator ranges from 0 to 3, and the total score is 24 points. The higher the score, the worse the sleep quality, and vise versa from baseline to 1 month
Secondary change score of AIS Sleep Scale The Athens Insomnia Scale (AIS) can help patients quantitatively self-evaluate sleep disorders with a psychometric instrument that includes eight indicators for sleep induction, awakenings during the night, final awakening, total sleep duration, sleep quality during the night, wellbeing during the night, functioning capacity during the day time, and sleepiness during the day time. The score for each indicator ranges from 0 to 3, and the total score is 24 points. The higher the score, the worse the sleep quality, and vise versa from baseline to 2 months
Secondary change score of AIS Sleep Scale The Athens Insomnia Scale (AIS) can help patients quantitatively self-evaluate sleep disorders with a psychometric instrument that includes eight indicators for sleep induction, awakenings during the night, final awakening, total sleep duration, sleep quality during the night, wellbeing during the night, functioning capacity during the day time, and sleepiness during the day time. The score for each indicator ranges from 0 to 3, and the total score is 24 points. The higher the score, the worse the sleep quality, and vise versa from baseline to 3 months
Secondary change score of AIS Sleep Scale The Athens Insomnia Scale (AIS) can help patients quantitatively self-evaluate sleep disorders with a psychometric instrument that includes eight indicators for sleep induction, awakenings during the night, final awakening, total sleep duration, sleep quality during the night, wellbeing during the night, functioning capacity during the day time, and sleepiness during the day time. The score for each indicator ranges from 0 to 3, and the total score is 24 points. The higher the score, the worse the sleep quality, and vise versa from baseline to 6 months
Secondary change score of AIS Sleep Scale The Athens Insomnia Scale (AIS) can help patients quantitatively self-evaluate sleep disorders with a psychometric instrument that includes eight indicators for sleep induction, awakenings during the night, final awakening, total sleep duration, sleep quality during the night, wellbeing during the night, functioning capacity during the day time, and sleepiness during the day time. The score for each indicator ranges from 0 to 3, and the total score is 24 points. The higher the score, the worse the sleep quality, and vise versa from baseline to 12 months
Secondary rate of ACR20 at 2 weeks
Secondary rate of ACR20 ACR20 is met when =20% is achieved in the reduction of tender joint number, swollen joint number, and indexes of 3 of the 5 other measurements at 1 month
Secondary rate of ACR20 ACR20 is met when =20% is achieved in the reduction of tender joint number, swollen joint number, and indexes of 3 of the 5 other measurements at 2 months
Secondary rate of ACR20 ACR20 is met when =20% is achieved in the reduction of tender joint number, swollen joint number, and indexes of 3 of the 5 other measurements at 3 months
Secondary rate of ACR20 ACR20 is met when =20% is achieved in the reduction of tender joint number, swollen joint number, and indexes of 3 of the 5 other measurements at 6 months
Secondary rate of ACR20 ACR20 is met when =20% is achieved in the reduction of tender joint number, swollen joint number, and indexes of 3 of the 5 other measurements at 12 months
Secondary rate of ACR70 ACR70 is met when =70% is achieved in the reduction of tender joint number, swollen joint number, and indexes of 3 of the 5 other measurements at 2 weeks
Secondary rate of ACR70 ACR70 is met when =70% is achieved in the reduction of tender joint number, swollen joint number, and indexes of 3 of the 5 other measurements at 1 month
Secondary rate of ACR70 ACR70 is met when =70% is achieved in the reduction of tender joint number, swollen joint number, and indexes of 3 of the 5 other measurements at 2 months
Secondary rate of ACR70 ACR70 is met when =70% is achieved in the reduction of tender joint number, swollen joint number, and indexes of 3 of the 5 other measurements at 3 months
Secondary rate of ACR70 ACR70 is met when =70% is achieved in the reduction of tender joint number, swollen joint number, and indexes of 3 of the 5 other measurements at 6 months
Secondary rate of ACR70 ACR70 is met when =70% is achieved in the reduction of tender joint number, swollen joint number, and indexes of 3 of the 5 other measurements at 12 months
See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4